^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Zejula (niraparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Acceptable Recurrence Therapies for Epithelial Ovarian (including LCOC) /Fallopian Tube/Primary Peritoneal Cancer...Recurrence Therapy for Platinum-Sensitive Disease...Other Recommended Regimens...Targeted Therapy...Niraparib/bevacizumab
